News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
238,832 Results
Type
Article (13390)
Company Profile (22)
Press Release (225420)
Multimedia
Podcasts (11)
Webinars (2)
Section
Business (71387)
Career Advice (1114)
Deals (14433)
Drug Delivery (39)
Drug Development (34517)
Employer Resources (47)
FDA (6602)
Job Trends (5790)
News (125331)
Policy (10329)
Tag
Academia (764)
Accelerated approval (2)
Adcomms (7)
Allergies (51)
Alliances (11240)
ALS (51)
Alzheimer's disease (555)
Antibody-drug conjugate (ADC) (77)
Approvals (6671)
Artificial intelligence (137)
Autoimmune disease (17)
Automation (10)
Bankruptcy (110)
Best Places to Work (4936)
BIOSECURE Act (4)
Biosimilars (64)
Biotechnology (20)
Bladder cancer (70)
Brain cancer (22)
Breast cancer (210)
Cancer (1527)
Cardiovascular disease (105)
Career advice (886)
Career pathing (9)
CAR-T (74)
Cell therapy (224)
Cervical cancer (13)
Clinical research (30065)
Collaboration (461)
Compensation (249)
Complete response letters (2)
COVID-19 (1011)
CRISPR (23)
C-suite (86)
Cystic fibrosis (41)
Data (1660)
Depression (21)
Diabetes (158)
Diagnostics (2313)
Digital health (9)
Diversity, equity & inclusion (13)
Drug discovery (60)
Drug pricing (42)
Drug shortages (11)
Duchenne muscular dystrophy (69)
Earnings (51225)
Editorial (15)
Employer branding (10)
Employer resources (43)
Events (33842)
Executive appointments (353)
FDA (7446)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (1)
Frontotemporal dementia (6)
Funding (463)
Gene editing (61)
Generative AI (8)
Gene therapy (171)
GLP-1 (437)
Government (1523)
Grass and pollen (4)
Guidances (161)
Healthcare (6834)
Huntington's disease (11)
IgA nephropathy (19)
Immunology and inflammation (65)
Indications (17)
Infectious disease (1103)
Inflammatory bowel disease (61)
Inflation Reduction Act (3)
Influenza (45)
Intellectual property (41)
Interviews (195)
IPO (8474)
IRA (11)
Job creations (1182)
Job search strategy (771)
Kidney cancer (9)
Labor market (20)
Layoffs (168)
Leadership (6)
Legal (2102)
Liver cancer (42)
Lung cancer (241)
Lymphoma (117)
Machine learning (5)
Management (11)
Manufacturing (158)
MASH (46)
Medical device (4899)
Medtech (4901)
Mergers & acquisitions (6364)
Metabolic disorders (432)
Multiple sclerosis (56)
NASH (11)
Neurodegenerative disease (56)
Neuropsychiatric disorders (20)
Neuroscience (874)
NextGen: Class of 2025 (2070)
Non-profit (1533)
Now hiring (25)
Obesity (236)
Opinion (71)
Ovarian cancer (39)
Pain (52)
Pancreatic cancer (52)
Parkinson's disease (92)
Partnered (7)
Patents (98)
Patient recruitment (51)
Peanut (27)
People (8494)
Pharmaceutical (11)
Pharmacy benefit managers (5)
Phase I (8055)
Phase II (12973)
Phase III (11540)
Pipeline (1168)
Policy (41)
Postmarket research (1211)
Preclinical (2737)
Press Release (15)
Prostate cancer (74)
Psychedelics (16)
Radiopharmaceuticals (98)
Rare diseases (196)
Real estate (1328)
Recruiting (19)
Regulatory (7758)
Reports (23)
Research institute (780)
Resumes & cover letters (207)
Rett syndrome (6)
RNA editing (1)
RSV (28)
Schizophrenia (48)
Series A (73)
Series B (51)
Service/supplier (3)
Sickle cell disease (29)
Special edition (8)
Spinal muscular atrophy (82)
Sponsored (11)
Startups (1140)
State (1)
Stomach cancer (5)
Supply chain (42)
Tariffs (18)
The Weekly (11)
Vaccines (365)
Venture capitalists (22)
Weight loss (156)
Women's health (10)
Worklife (8)
Date
Last 7 days (363)
Last 30 days (2278)
Last 365 days (18084)
2025 (8117)
2024 (16897)
2023 (16187)
2022 (20646)
2021 (20272)
2020 (19028)
2019 (16794)
2018 (12749)
2017 (11970)
2016 (10566)
2015 (12716)
2014 (9228)
2013 (7262)
2012 (7941)
2011 (8061)
2010 (7267)
Location
Africa (317)
Alabama (19)
Alaska (2)
Arizona (61)
Arkansas (5)
Asia (15405)
Australia (2362)
California (3792)
Canada (1136)
China (330)
Colorado (159)
Connecticut (212)
Delaware (129)
Europe (34247)
Florida (477)
Georgia (103)
Idaho (15)
Illinois (294)
India (9)
Indiana (174)
Iowa (5)
Japan (136)
Kansas (45)
Kentucky (7)
Louisiana (6)
Maine (41)
Maryland (448)
Massachusetts (2739)
Michigan (86)
Minnesota (169)
Mississippi (2)
Missouri (44)
Montana (8)
Nebraska (4)
Nevada (35)
New Hampshire (27)
New Jersey (1096)
New Mexico (8)
New York (1027)
North Carolina (455)
North Dakota (3)
Northern California (1654)
Ohio (88)
Oklahoma (4)
Oregon (12)
Pennsylvania (729)
Puerto Rico (8)
Rhode Island (10)
South America (465)
South Carolina (12)
Southern California (1393)
Tennessee (48)
Texas (573)
United States (13419)
Utah (84)
Virginia (97)
Washington D.C. (28)
Washington State (371)
West Virginia (3)
Wisconsin (54)
238,832 Results for "5".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Venture capitalists
The Top 5 Most Active Corporate VCs in Pharma
BioSpace
examines the busiest corporate venture capital arms in the pharmaceutical industry. Novo Holdings, which made headlines last year with its $16.5 billion Catalent buy, topped the list.
May 21, 2025
·
5 min read
·
Annalee Armstrong
Press Releases
Ritedose Pharmaceuticals Receives FDA Approval for Albuterol Sulfate Inhalation Solution, 0.5% (2.5 mg/0.5 mL)*--Addressing Nationwide Shortage of the Essential Drug
May 20, 2025
·
3 min read
Layoffs
The 5 Largest Biopharma Layoffs of Q1 2025: Updated
The number of employees laid off increased year over year during the first quarter.
BioSpace
recaps the five largest rounds of layoffs, which included BMS and Novartis cuts.
May 13, 2025
·
5 min read
·
Angela Gabriel
Press Releases
Pasithea Therapeutics Announces Closing of $5 Million Public Offering
May 8, 2025
·
5 min read
Press Releases
Pasithea Therapeutics Announces Pricing of $5 Million Public Offering
May 7, 2025
·
4 min read
Press Releases
MicroGenDX Launches “Rapid H5,” a PCR Test for H5 Influenza Detection
March 3, 2025
·
2 min read
Press Releases
Number of Shares and Voting Rights of Innate Pharma as of May 5, 2025
May 12, 2025
·
4 min read
Press Releases
Theriva Biologics Announces Pricing of $7.5 Million Public Offering
May 7, 2025
·
5 min read
Press Releases
Nika Pharmaceuticals, Inc. (NIKA) Markets Analysis and €8.5 Billion Projected Revenue
May 19, 2025
·
3 min read
Radiopharmaceuticals
5 Big Pharmas Push Boundaries in Radiopharmaceuticals
While Novartis and Bayer got there first, AstraZeneca, Bristol Myers Squibb and Eli Lilly are all vying to bring their radiopharmaceutical assets to a market projected to be worth over $13 billion by 2033.
March 31, 2025
·
9 min read
·
Tristan Manalac
1 of 23,884
Next
